← Back to headlines
Celldex Prices $300M Stock Offering to Fund Barzolvolimab Launch
Celldex Therapeutics has priced a $300 million stock offering at $29 per share, with proceeds intended to fuel the launch of its drug Barzolvolimab.
2 Apr, 06:08 — 2 Apr, 06:08
Sources
Showing 1 of 1 sources
